Comparison Overview

The Janssen Pharmaceutical Companies of Johnson & Johnson

VS

Johnson & Johnson Innovative Medicine

The Janssen Pharmaceutical Companies of Johnson & Johnson

1000 U.S. Highway 202, Raritan, New Jersey, US
Last Update: 2025-12-09
View Profile
Between 750 and 799
http://www.janssen.com

At Janssen, we never stop working toward a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, and you can count on us to keep working tirelessly to make that future a reality for patients everywhere, by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Arterial Hypertension. Visit us: www.janssen.com Follow us: @JanssenGlobal on Twitter and Instagram Watch our videos on our YouTube channel: http://bit.ly/1LY2xQ5

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 14,253
Subsidiaries: 1
12-month incidents
0
Known data breaches
0
Attack type number
0
View Profile

Johnson & Johnson Innovative Medicine

None
Last Update: 2025-12-09
Between 750 and 799
https://innovativemedicine.jnj.com/

At Johnson & Johnson Innovative Medicine, we innovate with purpose, to lead where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential medicines of tomorrow. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. https://bit.ly/3reuMvK

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 17,292
Subsidiaries: 10
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/janssen-pharmaceutical-companies-of-johnson-and-johnson.jpeg
The Janssen Pharmaceutical Companies of Johnson & Johnson
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/jnjinnovativemedicine.jpeg
Johnson & Johnson Innovative Medicine
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
The Janssen Pharmaceutical Companies of Johnson & Johnson
100%
Compliance Rate
0/4 Standards Verified
Johnson & Johnson Innovative Medicine
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for The Janssen Pharmaceutical Companies of Johnson & Johnson in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Johnson & Johnson Innovative Medicine in 2025.

Incident History — The Janssen Pharmaceutical Companies of Johnson & Johnson (X = Date, Y = Severity)

The Janssen Pharmaceutical Companies of Johnson & Johnson cyber incidents detection timeline including parent company and subsidiaries

Incident History — Johnson & Johnson Innovative Medicine (X = Date, Y = Severity)

Johnson & Johnson Innovative Medicine cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/janssen-pharmaceutical-companies-of-johnson-and-johnson.jpeg
The Janssen Pharmaceutical Companies of Johnson & Johnson
Incidents

No Incident

https://images.rankiteo.com/companyimages/jnjinnovativemedicine.jpeg
Johnson & Johnson Innovative Medicine
Incidents

No Incident

FAQ

Johnson & Johnson Innovative Medicine company demonstrates a stronger AI Cybersecurity Score compared to The Janssen Pharmaceutical Companies of Johnson & Johnson company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Historically, Johnson & Johnson Innovative Medicine company has disclosed a higher number of cyber incidents compared to The Janssen Pharmaceutical Companies of Johnson & Johnson company.

In the current year, Johnson & Johnson Innovative Medicine company and The Janssen Pharmaceutical Companies of Johnson & Johnson company have not reported any cyber incidents.

Neither Johnson & Johnson Innovative Medicine company nor The Janssen Pharmaceutical Companies of Johnson & Johnson company has reported experiencing a ransomware attack publicly.

Neither Johnson & Johnson Innovative Medicine company nor The Janssen Pharmaceutical Companies of Johnson & Johnson company has reported experiencing a data breach publicly.

Neither Johnson & Johnson Innovative Medicine company nor The Janssen Pharmaceutical Companies of Johnson & Johnson company has reported experiencing targeted cyberattacks publicly.

Neither The Janssen Pharmaceutical Companies of Johnson & Johnson company nor Johnson & Johnson Innovative Medicine company has reported experiencing or disclosing vulnerabilities publicly.

Neither The Janssen Pharmaceutical Companies of Johnson & Johnson nor Johnson & Johnson Innovative Medicine holds any compliance certifications.

Neither company holds any compliance certifications.

Johnson & Johnson Innovative Medicine company has more subsidiaries worldwide compared to The Janssen Pharmaceutical Companies of Johnson & Johnson company.

Johnson & Johnson Innovative Medicine company employs more people globally than The Janssen Pharmaceutical Companies of Johnson & Johnson company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither The Janssen Pharmaceutical Companies of Johnson & Johnson nor Johnson & Johnson Innovative Medicine holds SOC 2 Type 1 certification.

Neither The Janssen Pharmaceutical Companies of Johnson & Johnson nor Johnson & Johnson Innovative Medicine holds SOC 2 Type 2 certification.

Neither The Janssen Pharmaceutical Companies of Johnson & Johnson nor Johnson & Johnson Innovative Medicine holds ISO 27001 certification.

Neither The Janssen Pharmaceutical Companies of Johnson & Johnson nor Johnson & Johnson Innovative Medicine holds PCI DSS certification.

Neither The Janssen Pharmaceutical Companies of Johnson & Johnson nor Johnson & Johnson Innovative Medicine holds HIPAA certification.

Neither The Janssen Pharmaceutical Companies of Johnson & Johnson nor Johnson & Johnson Innovative Medicine holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

NXLog Agent before 6.11 can load a file specified by the OPENSSL_CONF environment variable.

Published
Date
2025-12-14
Updated
Date
2025-12-14
Risk Information
cvss3
Base: 8.1
Severity: HIGH
CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:C/C:H/I:H/A:H
References
Description

uriparser through 0.9.9 allows unbounded recursion and stack consumption, as demonstrated by ParseMustBeSegmentNzNc with large input containing many commas.

Published
Date
2025-12-14
Updated
Date
2025-12-14
Risk Information
cvss3
Base: 2.9
Severity: HIGH
CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:U/C:N/I:N/A:L
References
Description

A vulnerability was detected in Mayan EDMS up to 4.10.1. The affected element is an unknown function of the file /authentication/. The manipulation results in cross site scripting. The attack may be performed from remote. The exploit is now public and may be used. Upgrading to version 4.10.2 is sufficient to fix this issue. You should upgrade the affected component. The vendor confirms that this is "[f]ixed in version 4.10.2". Furthermore, that "[b]ackports for older versions in process and will be out as soon as their respective CI pipelines complete."

Published
Date
2025-12-14
Updated
Date
2025-12-14
Risk Information
cvss2
Base: 5.0
Severity: LOW
AV:N/AC:L/Au:N/C:N/I:P/A:N
cvss3
Base: 4.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:N/I:L/A:N
cvss4
Base: 5.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

MJML through 4.18.0 allows mj-include directory traversal to test file existence and (in the type="css" case) read files. NOTE: this issue exists because of an incomplete fix for CVE-2020-12827.

Published
Date
2025-12-14
Updated
Date
2025-12-14
Risk Information
cvss3
Base: 4.5
Severity: HIGH
CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:C/C:L/I:N/A:L
References
Description

A half-blind Server Side Request Forgery (SSRF) vulnerability exists in kube-controller-manager when using the in-tree Portworx StorageClass. This vulnerability allows authorized users to leak arbitrary information from unprotected endpoints in the control plane’s host network (including link-local or loopback services).

Published
Date
2025-12-14
Updated
Date
2025-12-14
Risk Information
cvss3
Base: 5.8
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:H/UI:N/S:C/C:H/I:N/A:N
References